AOArlette Odink

Arlette Odink

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arlette Odink has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gas chromatography-mass spectrometry exhaled breath analysis for phenotyping interstitial lung disease- an exploratory study

    by Iris G van der Sar, Iris A Simons, Roxanne F G van Duren, Esther J Nossent, Marlies S Wijsenbeek, JanWillem Duitman, Arlette E Odink, Lilian J Meijboom, Catharina C Moor, Paul Brinkman

    Interstitial lung disease (ILD) encompasses pulmonary disorders characterised by varying degrees of inflammation and/or fibrosis. The presence and extent of these pulmonary abnormalities on (high-resolution) computed tomography (CT) have consequences for diagnosis and treatment; however, inter-observer assessment varies. Analysis of exhaled volatile organic compounds (VOCs) through gas chromatography-mass spectrometry (GC-MS) offers a noninvasive approach to biomarker discovery and pathophysiology understanding. Our study aims to explore the ability of GC-MS-driven exhaled breath analysis to differentiate ILD patients with predominant fibrotic, inflammatory, or a combination of fibrotic and inflammatory pulmonary abnormalities in a training and an external validation cohort. In a multicentre cross-sectional study, patients diagnosed with ILD were recruited. After central review of chest CT scans by independent radiologists, patients were categorised as fibrotic, inflammatory or mixed phenotype group based on the percentage of chest CT scan abnormalities. Breath samples were collected and analysed via GC-MS. Significantly different VOC fragments between groups were selected and used to differentiate groups in the training cohort with sparse partial least squares discriminant analysis. Analyses were validated with patients from an external cohort. 53 patients were included, 21 patients in the fibrotic, 14 in the inflammatory and 18 in the mixed phenotype group. Area under the curve (AUCs) for discrimination between groups ranged from 0.89–1.00 in training cohorts. An attempt to confirm these findings in our external validation cohort resulted in AUCs of 0.63–0.84. Re-evaluation of the training model led to an AUC of 0.78–0.83. This study shows that GC-MS driven exhaled breath analysis towards differentiation of ILD phenotypes is challenging. Current findings emphasise the importance of predefined validation steps during the process of biomarker discovery.


  • Open Access

    Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes

    by Merel E. Hellemons, Susanne Huijts, L. Martine Bek, Julia C. Berentschot, Gizal Nakshbandi, Carin A. M. Schurink, Johan H. Vlake, Michel E. van Genderen, Jasper van Bommel, Diederik Gommers, et al.

    Rationale: Data on longitudinal recovery after hospitalization for coronavirus disease (COVID-19) currently remain scarce, just as outcomes beyond 3 months of follow-up do. Objectives: To evaluate the sequelae up to 6 months after hospitalization for COVID-19 by considering 1) recovery as it relates to pulmonary function, radiological abnormalities, physical and mental health status, and health-related quality of life (HR-QoL) and 2) the predictors of the most clinically relevant sequelae. Methods: Patients were evaluated at 6 weeks, 3 months, and 6 months after hospitalization by using pulmonary function testing, radiological evaluation, and online questionnaires on the physical and mental health status and HR-QoL. Outcomes were analyzed using repeated-measurement analyses. Results: Ninety-two patients were included (mean age, 58.2 ± 12.3 yr; 58 [63.0%] men). The estimated percentage of patients with impaired forced vital capacity improved from 25% at 6 weeks to 11% at 6 months; for impaired diffusion capacity, this percentage improved from 63% to 46%. Radiologically, ground-glass opacity decreased but fibrosis persisted. The majority of patients (89.1%) still reported one or more symptoms 6 months after discharge. Fatigue decreased significantly over time (P = 0.006). Nonetheless, fatigue remained in 51% of the patients at 6 months. HR-QoL (nearly) normalized in most domains at 6 months, except for physical role functioning, with persistent fatigue and the length of hospitalization being the most important predictors. Conclusions: During the first 6 months after hospitalization for COVID-19, most patients demonstrated continuing recovery across all health domains, but persistent sequelae were frequent. Fatigue was the most frequent residual and persistent symptom up to 6 months after hospitalization, importantly impacting HR-QoL.